16Jun
Diligence Clauses and the Management of Uncertainty in Life Sciences Agreements
In times of uncertainty and disruption, setting expectations for performance with business partners and contractual counterparties can be more complicated than ever. Companies that develop drugs, biologics and medical devices have considerable...
By:
Skadden, Arps, Slate, Meagher & Flom LLP
Related
Horton v. Organogenesis Inc.,C.A. No. 2018-0537-KSJM (Del. Ch. July 22, 2019). Sellers in merger ag...
Read More >
On February 1, 2021, the Federal Trade Commission (FTC) announced revised jurisdictional thresholds ...
Read More >
As the coronavirus disease 2019 (COVID-19) continues to spread, U.S. employers considering taking pr...
Read More >
he last time the Department of Justice’s Antitrust Division and the Federal Trade Commission (the A...
Read More >
What is the Annual Maximum Out-Of-Pocket Limit (“MOOP”)? MOOP is the most a participant must pay ...
Read More >
The uptick in ICE investigations has Oregon requiring employers to notify employees of any upcoming ...
Read More >